Lipella pharmaceuticals announces fda clearance of ind for lp-410 for oral graft-versus-host disease, advancing clinical pipeline

Pittsburgh, march 05, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: “lipo”) (“lipella,” “our, “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the u.s. food and drug administration (fda) has approved an investigational new drug (ind) application for clinical testing of lp-410 in the treatment of oral graft-versus-host disease (gvhd). lipella's clinical study, titled, a multicenter, dose-ranging trial evaluating the safety, tolerability, and efficacy of lp-410 in subjects with symptomatic oral gvhd, is expected to commence in the second half of 2024.
LIPO Ratings Summary
LIPO Quant Ranking